研究：Zepbound（替泽帕肽）除了可以减轻体重和控制糖尿病外，还可以降低肥胖患者的收缩压。 Study: Zepbound (tirzepatide) reduces systolic blood pressure in obesity patients besides weight loss and diabetes control.

一项新的研究表明，减肥药 Zepbound（也称为替泽帕肽）不仅能减轻体重和控制糖尿病，还能提供更多的健康益处。 A new study shows that the weight-loss drug Zepbound, also known as tirzepatide, provides more health benefits than just dropping pounds and controlling diabetes. 它还可以帮助肥胖症患者控制高血压。 It also helps people with obesity manage their high blood pressure. 服用 Zepbound 的患者的收缩压显着降低，这是血压读数中最高的数字。 Patients taking Zepbound experienced a significant reduction in their systolic blood pressure, the top number in a blood pressure reading. 该研究发表在《高血压》杂志上，发现服用较高剂量药物的参与者的收缩压下降幅度更大。 The study was published in the journal Hypertension and found that participants taking higher doses of the drug experienced greater reductions in their systolic blood pressure.